Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17774845 | 0.85 | ALOX5 (0.50) | NAAAALOX5PTGS2SYKEGFR | |
| SCHEMBL12041032 | 0.84 | TDP1 (0.51) | NAAAALOX5PTGS2CDK1KDM4E | |
| SCHEMBL12041029 | 0.81 | NAAA (0.60) | NAAAALOX5KDM4ELMNAGAA | |
| Gentisic Acid Ethanolamide SCHEMBL1179368 | 0.80 | NAAA (0.65) | NAAAALOX5PTGS2SYKEGFR | |
| Gentisic Acid Ethanolamide SCHEMBL29379843 | 0.80 | NAAA (0.65) | NAAAALOX5PTGS2SYKEGFR | |
| SCHEMBL12041038 | 0.79 | TDP1 (0.59) | NAAAPTGS2EGFRCDK1KDM4E | |
| SCHEMBL6185423 | 0.78 | NAAA (0.40) | NAAAALOX5PTGS2SYKEGFR | |
| SCHEMBL6619566 | 0.77 | NAAA (0.40) | NAAAALOX5PTGS2SYKEGFR | |
| SCHEMBL9785906 | 0.77 | NAAA (1.00) | NAAAALOX5PTGS2SYKEGFR | |
| SCHEMBL5488260 | 0.77 | NAAA (1.00) | NAAAALOX5PTGS2SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| WO-2009124371-A9 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2010-12-02 | — | — | WO | disclosed |
| WO-2009124371-A2 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S. A. (BR) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | NAAA 255/4885ALOX5 433/4885PTGS2 217/4885 |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | NAAA 255/4885ALOX5 433/4885PTGS2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.